Select your Market

Global
Africa
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Congo Democratic Republic
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Ivory Coast
Kenya
Lesotho
Liberia
Libya
Madagascar
Malawi
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Reunion Islands
Rwanda
Saint Helena
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Asia
Bahrain
Bangladesh
China, mainland
India
Indonesia
Iran
Iraq
Israel
Japan
Jordan
Kuwait
Lebanon
Malaysia
Oman
Palestine
Philippines
Qatar
Saudi Arabia
Singapore
South Korea
Syria
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Yemen
Europe
Albania
Austria
Baltic Region
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
Latin America
Argentina
Aruba
Bahamas
Barbados
Belize
Bolivia
Brazil
Central America
Chile
Colombia
Costa Rica
Cuba
Curacao-NL Antillen
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Nicaragua
Panama
Paraguay
Perú
República Dominicana
Trinidad and Tobago
Uruguay
Venezuela
North America
Canada
United States of America
Oceania
Australia
New Zealand
Global
  1. Press Releases

Collaboration with Versant to Launch Saturnus Bio

Merck KGaA, Darmstadt, Germany Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies

Subscribe
23 Jun 2026 | Darmstadt, Germany
  • Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need.
  • The collaboration will augment Merck KGaA, Darmstadt, Germany’s efforts to pursue precision medicine-defined indications.

Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments.

“Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Research and Development and Chief Medical Officer at Merck KGaA, Darmstadt, Germany. “By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients.”

“The launch of Saturnus through a foundational partnership with Merck KGaA, Darmstadt, Germany exemplifies Versant’s strategy of engaging with pharma to develop a new frontier of medicines in areas of important unmet medical need,” said Rick Dewey, MD, an entrepreneur-in-residence at Versant Ventures and CEO of Saturnus. “The company is in strong position to accelerate development of its pipeline of first-in-class medicines for genetic cardiomyopathies.”

The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus' research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus for a pre-determined option payment in addition to success-based earnouts.

The strategic partnership will focus on next-generation precision cardiology that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Genetic cardiomyopathies represent a vital entry point for Merck KGaA, Darmstadt, Germany's cardiovascular business, addressing a significant unmet need in a market characterized by no approved therapies for genetic drivers.

Merck KGaA, Darmstadt, Germany, is committed to leveraging advanced technologies and data science to accelerate the discovery and delivery of breakthrough medicines. This partnership reinforces its broader strategy to enhance research productivity and the output of its pipeline sustainably, focusing on indications that can be derisked through proper preclinical and early clinical testing to ensure that more patients gain access to effective treatments.

Downloads

For more information, contact Melissa Beglin
+1 781 206 4951

About Merck KGaA, Darmstadt, Germany 

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck KGaA, Darmstadt, Germany, generated sales of € 21.1 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.

Related News

  1. Press Releases

    2026 Future Insight Prize Goes to Spear’s Vasilis Ntziachristos

    The € 300,000 research grant award recognizes Ntziachristos’ pioneering work in enabling non-invasive and continuous monitoring of human biology.

    2026/06/23